P.A.R.T. Texas Glossary
A quick-reference guide to common abbreviations and terms used in pain management and opioid policy.
A
- Addiction
- A chronic condition characterized by compulsive drug use despite harmful consequences. Distinct from physical dependence or tolerance.
- AcetaminophenDrug
- A common non-opioid analgesic used to reduce pain and fever. Often combined with opioids (e.g., hydrocodone/acetaminophen) for added pain relief.
- AnalgesicCategory
- A medicine used to relieve pain. Includes non-opioids (acetaminophen, NSAIDs) and opioids such as hydrocodone and oxycodone (full agonist pain medications).
- Aggregate Data / Aggregated Statistical Sets
-
Aggregate data means information from many people combined together, without names or details that point to any one person.
Instead of focusing on an individual, we look at the overall patterns.
Example: instead of saying “John Smith was cut off of his pain medication,” we might say, “67 members reported forced tapers between 2022 and 2025.” That is aggregate data. When we say your information may remain in aggregated statistical sets, we mean your story may still be counted in those combined numbers and charts, but it will not be identifiable as you.
B
- Belbuca
- A brand of buprenorphine approved for chronic pain. It’s a buccal film placed against the cheek to dissolve (no naloxone included).
- Buccal
- Inside the cheek. Example: Belbuca is a buccal film placed against the cheek to dissolve.
- BuprenorphineDrug
- A partial opioid agonist used for chronic pain (e.g., Belbuca) and for OUD (e.g., Suboxone, Zubsolv).
C
- COTAcronym
- Chronic Opioid Therapy — long-term use of opioid medications for pain management under medical supervision.
- Ceiling EffectPharmacology
- The point at which increasing a drug’s dose does not produce additional therapeutic effect, but may increase side effects.
For partial opioid agonists like buprenorphine, this limits maximum pain relief and respiratory depression.
FDA (2023): “At higher doses, buprenorphine shows a plateau in effect on respiratory depression, which may reduce—but does not eliminate—the risk of overdose compared to full agonists.”
D
- DEAAgency
- Drug Enforcement Administration — U.S. agency that enforces controlled-substance laws (scheduling, registrations, inspections).
- Dental Warning (2022 FDA)
- In January 2022, FDA added a class-wide warning for buprenorphine products that dissolve in the mouth (buccal/sublingual) about increased risk of cavities, decay, and tooth loss. Hygiene advice: let the dose dissolve fully, rinse afterward, and wait ≥1 hour before brushing.
- DepressionCondition
- A common mental health condition marked by persistent sadness, loss of interest, changes in sleep or appetite, and difficulty concentrating. Severity can range from mild to severe.
- DilaudidBrand
- Brand of hydromorphone used for moderate to severe pain (available in immediate-release and injectable forms).
- DSM-5 CriteriaReference
- Diagnostic and Statistical Manual of Mental Disorders, 5th Edition — the standard classification system for mental health conditions. Provides diagnostic criteria for disorders including Opioid Use Disorder and depression.
E
- Exalgo ERBrand
- Brand of extended-release hydromorphone used for long-term, around-the-clock management of pain in opioid-tolerant patients.
F
- FDAAgency
- U.S. Food and Drug Administration — federal agency that regulates drugs and issues safety communications and labeling requirements.
- Full Opioid AgonistPharmacology
- An opioid that fully activates the mu-opioid receptor (e.g., hydrocodone, oxycodone, morphine). These are common pain medications with no built-in ceiling effect.
H
- HIPAA
- Health Insurance Portability and Accountability Act — U.S. law protecting health information privacy and security. Note: HIPAA generally governs covered entities (providers, plans, clearinghouses), not most schools or employers.
- Heterogeneous StudiesResearch
- Studies that differ in populations, methods, or interventions. High heterogeneity makes pooling results (meta-analysis) harder and findings less comparable.
- HydrocodoneDrug
-
A full opioid agonist pain medication commonly prescribed for moderate to severe pain.
Brands: Norco (hydrocodone/acetaminophen), Hysingla ER (hydrocodone ER), Zohydro ER (hydrocodone ER). - Hysingla ERBrand
- Brand of extended-release hydrocodone for around-the-clock pain treatment.
- HydromorphoneDrug
- A full opioid agonist analgesic for moderate to severe pain. Brand: Dilaudid.
I
M
- MAT / MOUDAcronym
- Medication-Assisted Treatment / Medications for Opioid Use Disorder — use of FDA-approved medications (e.g., Suboxone, methadone, naltrexone) with counseling/support.
- MDLLegal
- Multidistrict Litigation — a federal process that consolidates many similar lawsuits into one court for efficiency.
- MorphineDrug
- A full opioid agonist pain medication derived from the opium poppy. Commonly used in hospitals for moderate to severe pain.
- Mu-Opioid ReceptorPharmacology
- The primary receptor in the nervous system that mediates the pain-relieving and euphoric effects of opioids. Activated strongly by full agonists (e.g., morphine, hydrocodone, oxycodone) and partially by partial agonists like buprenorphine.
- MMEMetric
- Morphine Milligram Equivalent — a standardized way to compare the potency of different opioids to morphine. One MME equals the strength of 1 mg of oral morphine. Used in guidelines, research, and prescription monitoring to estimate relative opioid dose and overdose risk. Example: 10 mg of hydrocodone ≈ 10 MME; 10 mg of oxycodone ≈ 15 MME.
N
- NaloxoneDrug
- An opioid antagonist used to reverse overdose (e.g., Narcan); included with buprenorphine in Suboxone as a misuse deterrent.
- NarcanBrand
- A brand name for naloxone, often available as a nasal spray. Rapidly restores normal breathing during an opioid overdose emergency.
- NorcoBrand
- Brand combining hydrocodone + acetaminophen for pain relief.
- NSAIDsDrug class
- Nonsteroidal Anti-Inflammatory Drugs — medications (e.g., ibuprofen, naproxen) that relieve pain, reduce fever, and decrease inflammation. Classified as analgesics but not opioids.
- NDA (Non-Disclosure Agreement)Legal
-
NDA stands for Non-Disclosure Agreement.
It is a legally binding contract that requires a person to keep certain information private and not share it without permission.
When we say our intake team or board members have signed NDAs, we mean they have made a legal promise not to disclose identifying details from your story except in the limited, clearly described ways you have authorized.
O
- OUDAcronym
- Opioid Use Disorder — the medical diagnosis for problematic opioid use causing distress or impairment (DSM-5 criteria).
- OxycodoneDrug
- A full opioid agonist pain medication commonly prescribed for moderate to severe pain.
P
- PDAcronym
- Physical Dependence — physiologic adaptation to a drug, leading to withdrawal if stopped suddenly. Not the same as addiction.
- PDMPAcronym
- Prescription Drug Monitoring Program — state-run electronic databases that track controlled-substance prescriptions to prevent misuse or diversion.
- PMP (Texas)State
- Prescription Monitoring Program — Texas’s PDMP system for tracking controlled-substance prescriptions. Related: PDMP.
- PCAAcronym
- Patient-Controlled Analgesia — pain control method allowing a patient to self-administer set doses (often via a pump).
- Palliative Care
- Specialized medical care focused on symptom relief and quality of life for people with serious illness.
- PPA / Pain Agreement
- Patient–Provider Agreement — a written understanding of treatment goals, safe-use rules, refills, monitoring (e.g., PDMP checks, UDTs), and responsibilities.
- Prior Authorization
- Insurer requirement for approval before covering a medication or procedure. Can delay care; appeals and exceptions may apply.
- Partial Opioid AgonistPharmacology
- An opioid that activates the mu-opioid receptor but with a built-in limit on its effects, known as the ceiling effect. Buprenorphine is the best-known example, used for both chronic pain and opioid use disorder. See also Full Opioid Agonist.
R
- TMB Rule 170.3Texas
- Texas Medical Board rule on Management of Chronic Pain (documentation, PDMP use, risk assessment, monitoring, etc.).
S
- Step Therapy
- Insurer policy requiring patients to try lower-cost/“preferred” options first and “fail” them before covering the prescribed treatment.
- Stigma
- Negative social judgments or discrimination related to pain treatment, opioid use, or the use of MOUD.
- SublocadeBrand
- Sublocade is an extended-release injectable form of buprenorphine used to treat opioid use disorder (OUD). It is administered as a monthly subcutaneous injection and provides continuous medication delivery over time.
- Sublingual
- Under the tongue. Example: Suboxone and Zubsolv dissolve here.
- Suboxone
- A sublingual combination of buprenorphine + naloxone approved for OUD. The naloxone discourages misuse if injected.
- SubutexBrand
- Subutex is a brand name for buprenorphine used in the treatment of opioid use disorder (OUD). It does not contain naloxone and is typically administered sublingually (under the tongue).
T
- Transmucosal
- Absorbed through the lining of the mouth; includes both buccal and sublingual routes.
- TMBTexas
- Texas Medical Board — licenses Texas physicians and adopts rules (e.g., Chapter 170) related to pain management and prescribing.
- TACTexas
- Texas Administrative Code — compilation of all state agency rules. TMB rules live in the TAC.
X
- XerostomiaSide effect
- Also called dry mouth — reduced or absent saliva production. Can be a side effect of medications, medical conditions, or treatments. May cause difficulty swallowing, speaking, or increased risk of cavities.
Z
- Zohydro ERBrand
- Brand of extended-release hydrocodone for long-acting pain control.
- Zubsolv
- A sublingual tablet of buprenorphine/naloxone for OUD. Carries the same 2022 FDA dental warning as other transmucosal products.